Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDERCompleted
NCT05945108N/AUpdated Apr 11, 2025
Sponsor: AstraZeneca
Urothelial Carcinoma · Non Muscle Invasive Bladder Cancer · Muscle-invasive Bladder Cancer
Brazil
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or PaclitaxelCompleted
NCT00516724Phase 1Updated Apr 11, 2025
Sponsor: AstraZeneca
Triple Negative Metastatic Breast Cancer · Advanced Ovarian Cancer · Carboplatin · Paclitaxel
Belgium, Netherlands, United Kingdom
Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLCCompleted
NCT03732274Phase 1, Phase 2Updated Apr 10, 2025
Sponsor: MedPacto, Inc.
Non-Small Cell Lung Cancer Metastatic
South Korea
Genomic Testing and Resulting Medical DecisionsCompleted
NCT03301493N/AUpdated Apr 10, 2025
Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Cancer of Unknown Origin · Cancer Refractory · Cancer of Stomach · Cancer Head Neck
Austria
Metastatic Breast Cancer in AustriaRecruiting
NCT03870620N/AUpdated Apr 10, 2025
Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Breast Cancer · Breast Carcinoma · Breast Tumor
Austria
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood CancerCompleted
NCT04630756Phase 1, Phase 2Updated Apr 9, 2025
Sponsor: AstraZeneca
Advanced Haematological Malignancies
United States, Australia, Canada, France, Ireland +4 more
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruiting
NCT03903835Phase 3Updated Apr 9, 2025
Sponsor: Karolinska Institutet
Metastatic Castration-resistant Prostate Cancer (mCRPC) · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Belgium, Norway, Sweden, Switzerland
A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In ChinaCompleted
NCT06422663N/AUpdated Apr 8, 2025
Sponsor: AstraZeneca
Moderate-to-Severe Asthma
China
A Study to Identify and Characterise Patients With Chronic Kidney Disease and ProteinuriaCompleted
NCT05967806N/AUpdated Apr 6, 2025
Sponsor: AstraZeneca
Renal Disease
United States, Argentina, Brazil, Canada, China +9 more
Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid TumoursCompleted
NCT04236414Phase 1Updated Apr 4, 2025
Sponsor: AstraZeneca
Solid Tumours
Denmark, France, Germany, South Korea, Spain +1 more
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)Completed
NCT04014075Phase 2Updated Apr 3, 2025
Sponsor: Daiichi Sankyo
Adenocarcinoma Gastric Stage IV With Metastases · Adenocarcinoma - GEJ
United States, Belgium, Italy, Spain, United Kingdom
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast CancerRecruiting
NCT06607757Phase 2Updated Apr 2, 2025
Sponsor: GBG Forschungs GmbH
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
Germany
HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in RussiaCompleted
NCT05905939N/AUpdated Apr 1, 2025
Sponsor: AstraZeneca
Breast Cancer
Russia
Ticagrelor With and Without Aspirin in Patients With Diabetes MellitusCompleted
NCT04484259Phase 4Updated Mar 30, 2025
Sponsor: University of Florida
Diabetes Mellitus, Type 2 · Coronary Artery Disease
United States
Disparities in the Proportion of Ticagrelor and Prasugrel-eligible Patients with Acute Coronary Syndrome in a Real-world RegistryCompleted
NCT05774431N/AUpdated Mar 30, 2025
Sponsor: University Hospital Heidelberg
Acute Myocardial Infarction
Germany
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal CancerTerminated
NCT04108481Phase 1Updated Mar 28, 2025
Sponsor: University of Iowa
Colorectal Cancer Metastatic · Colon Cancer · Metastatic Colorectal Cancer · Rectal Cancer
United States
Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical PracticeCompleted
NCT05250011N/AUpdated Mar 28, 2025
Sponsor: AstraZeneca
Heart Failure, Reduced Ejection Fraction
Italy
GLUcose Transport and REnalPROtection in Chronic Kidney DiseaseCompleted
NCT05998837Phase 2, Phase 3Updated Mar 28, 2025
Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Chronic Kidney Disease · Diabetes Mellitus, Type 2 · Hypertension
Italy
Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD PatientsCompleted
NCT03022097Phase 3Updated Mar 26, 2025
Sponsor: AstraZeneca
COPD
China, India, Philippines, Taiwan, Vietnam
Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).Terminated
NCT06406400Phase 1Updated Mar 26, 2025
Sponsor: AstraZeneca
Opioid Use Disorder
United States
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory ImagingCompleted
NCT05552508Phase 4Updated Mar 25, 2025
Sponsor: AstraZeneca
Asthma
United States, Australia, Belgium, France, Portugal +2 more
Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female SubjectsCompleted
NCT05790304Phase 1Updated Mar 25, 2025
Sponsor: AstraZeneca
Hepatic Impairment
United States, Bulgaria, Slovakia
Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic AdenocarcinomaCompleted
NCT02879318Phase 2Updated Mar 24, 2025
Sponsor: Canadian Cancer Trials Group
Pancreatic Adenocarcinoma
Canada
Abequolixron (RGX-104) and Durvalumab in Lung CancerTerminated
NCT05911308Phase 1Updated Mar 21, 2025
Sponsor: UNC Lineberger Comprehensive Cancer Center
Non-Small Cell Lung Cancer
United States
Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung CancerCompleted
NCT04003246Phase 2Updated Mar 21, 2025
Sponsor: University of Texas Southwestern Medical Center
Non Small Cell Lung Cancer · Lung Cancer Stage III
United States

Previous page Next page